Cover
Vol. 12 No. 1 (2022)

Published: June 30, 2022

Pages: 68-85

Research Article

The significance of PlGF in the progression of the ovarian hyperstimulation syndrome in patients undergoing an in vitro fertilization procedure.

Aliyah Dhahir Habeeb 1 Lubna Amer Al-Anbari Rehab Sh. Al-Maliki
1High Institute for Infertility Diagnosis and Assisted Reproductive Technologies, Al-Nahrain University, Baghdad, Iraq.
History
  • Received: May 7, 2022
  • Accepted: May 30, 2022
  • Available Online: June 12, 2022
DOI

https://doi.org/10.28969/IJEIR.v12.i1.r6.22

Abstract

Placenta growth factor is, VEGF family member, a Pleiotropic Factor affects a variety of cell types and regulates various biological responses. PlGF is similar in structure and function to VEGF, and it amplifies VEGF's angiogenic actions. Ovulation stimulation during cycles of in vitro fertilization (IVF) for the management of infertility results in ovarian hyperstimulation syndrome (OHSS), an iatrogenic side effect. Considering potential roles of PlGF and its receptor (sflt-1) in angiogenesis, the association of these factors with OHSS among study women during controlled ovarian stimulation have evaluated in the present study. Comparative cross-sectional study including of 60 women who go through controlled ovarian stimulation. On oocyte retrieval day, their serum and follicular fluid were taken. The concentrations of PlGF and sFlt-1 were assessed using ELISA .Eighteen patients presented with ovarian hyperstimulation syndrome (OHSS) and 42 patients were no OHSS. There was significantly higher serum PIGF in women with OHSS patients as compared to women with no OHSS, 141.4 ± 11.8 versus 91.9 ± 5.4 respectively (p<0.001). Furthermore, Follicular fluid PlGF there was significantly higher in women with OHSS patients as compared to women with no OHSS, 163.4 ± 7.2 versus 91.1 ± 5.5 respectively (p<0.001). Additionally Follicular fluids PlGF/sFlt ratio significantly higher in women with OHSS patients as compared to women with no OHSS, 0.034 ± 0.01 versus 0.026 ± 0.01 respectively (p<0 . 001). On the contrary there was significantly lower serum and follicular fluid sFlt in ovarian hyper-stimulated patients These statistics show that serum and FF PlGF and PlGF to sFlt ratio higher in women with ovarian hyperstimulation syndrome (OHSS) patients as compared to women with no OHSS. So, the PlGF may be played an important a role in angiogenesis dysregulation.

Keywords

References

  1. Naredi, N., Talwar, P. and Sandeep, K. (2014). VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status. Medical Journal Armed Forces India, 70 (1), pp.58–63. doi:10.1016/j.mjafi.2012.03.005.
  2. Nelson, S.M. (2017). Prevention and management of ovarian hyperstimulation syndrome. Thrombosis Research, 151, pp.S61–S64. doi:10.1016/s0049-3848 (17)30070-1.
  3. Sun, B., Ma, Y., Li, L., Hu, L., Wang, F., Zhang, Y., Dai, S. and Sun, Y. (2021). Factors Associated with Ovarian Hyperstimulation Syndrome (OHSS) Severity in Women With Polycystic Ovary Syndrome Undergoing IVF/ICSI. Frontiers in Endocrinology, [online] 11, p.615957. doi:10.3389/fendo.2020.615957.
  4. Namavar Jahromi, B., Parsanezhad, M.E., Shomali, Z., Bakhshai, P., Alborzi, M., Moin Vaziri, N. and Anvar, Z. (2018). Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management. Iranian Journal of Medical Sciences, [online] 43 (3), pp.248–260. Available at: https://pubmed.ncbi.nlm.nih.gov/29892142/
  5. Wise, L.M., Stuart, G.S., Real, N.C., Fleming, S.B. and Mercer, A.A. (2018). VEGF Receptor-2 Activation Mediated by VEGF-E Limits Scar Tissue Formation Following Cutaneous Injury. Advances in Wound Care, [online] 7 (8), pp.283–297. doi:10.1089/wound.2016.0721.
  6. Bender, H.R., Trau, H.A. and Duffy, D.M. (2018). Placental Growth Factor Is Required for Ovulation, Luteinization, and Angiogenesis in Primate Ovulatory Follicles. Endocrinology, [online] 159 (2), pp.710–722. doi:10.1210/en.2017-00739.
  7. Ceci, C., Atzori, M.G., Lacal, P.M. and Graziani, G. (2020). Role of VEGFs/VEGFR-1 Signaling and Its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models. International Journal of Molecular Sciences, [online] 21 (4). doi:10.3390/ijms21041388.
  8. Freitas-Andrade, M., Carmeliet, P., Charlebois, C., Stanimirovic, D.B. and Moreno, M.J. (2012). PlGF knockout delays brain vessel growth and maturation upon systemic hypoxic challenge. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism, [online] 32 (4), pp.663–675. doi:10.1038/jcbfm.2011.167.
  9. Corbett, S., Shmorgun, D., Claman, P., Cheung, A., Sierra, S., Carranza-Mamane, B., Case, A., Dwyer, C., Graham, J., Havelock, J., Healey, S., Hemmings, R., Liu, K., Motan, T., Murdock, W., Smithson, D., Vause, T., Wong, B. and Gysler, M. (2014). The Prevention of Ovarian Hyperstimulation Syndrome. Journal of Obstetrics and Gynaecology Canada, [online] 36 (11), pp.1024–1033. doi:10.1016/S1701-2163 (15) 30417-5.
  10. Albonici, L., Giganti, M.G., Modesti, A., Manzari, V. and Bei, R. (2019). Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression. International Journal of Molecular Sciences, 20 (12), p.2970. doi:10.3390/ijms20122970.
  11. Pan, P., Fu, H., Zhang, L., Huang, H., Luo, F., Wu, W., Guo, Y. and Liu, X. (2010). Angiotensin II upregulates the expression of placental growth factors in human vascular endothelial cells and smooth muscle cells. BMC Cell Biology, 11 (1), p.36. doi:10.1186/1471-2121-11-36.
  12. Alzaidi, Z., Yildiz, Ş.M., Saatçi, Ç. et al. The effect of cytokine leukemia- inhibitory factor (LIF) and interleukin-11 (IL-11) gene expression on the primary infertility related to polycystic ovary syndrome, Tubal factor, and Unexplained infertility in Turkish women. Egypt J Med Hum Genet 22, 85 (2021). https://doi.org/10.1186/s43042-021-00201- 9